Research Alliance Holdings III LLC disclosed a 14.7% stake in Research Alliance Corporation III. The Schedule 13D was filed on May 29, 2026, following the SPAC’s IPO and a concurrent private placement on May 21, 2026. The sponsor’s position combines founder shares and privately placed Class A shares, signaling continued control and support for the SPAC’s deal process.
Investor Intent
Research Alliance Holdings III LLC says it holds the shares for investment. Under a letter agreement, the sponsor agreed to "vote their shares in favor of any proposed initial business combination" and "not to redeem any shares" in that vote.
The group may buy more securities or sell holdings after the business combination, depending on how plans develop and market conditions. Matthew Hammond, the sponsor’s manager and the SPAC’s CEO and director, will stay engaged with the company’s board as it seeks a merger.
Investor's Background
Research Alliance Holdings III LLC is the sponsor of Research Alliance Corporation III and holds both founder shares and private placement shares. The sponsor is affiliated with RA Capital Management, a Boston-based investment firm known for concentrated, research-driven bets in biotech and life sciences. RA Capital often backs healthcare companies from early development through commercialization.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.